New Photocure White Paper: Beyond the buzzwords – How AI and advancing diagnostic technologies will transform early bladder cancer care
This new White Paper discusses how AI and advancing diagnostic technologies impact diagnoses and bladder cancer care. It also addresses the shift to a precision-based approach in NMIBC and the emergence of novel diagnostic technologies. The white paper includes recent medical literature as well as Photocure’s views on the impact of new diagnostic technologies and artificial intelligence within precision diagnostics in bladder cancer.
Read the full white paper online:
Beyond the buzzwords ‒ How AI and advancing diagnostic technologies will transform early bladder cancer care
“AI is intended to complement clinical practice, not replace decision making by clinicians. By combining AI with enhanced imaging technology and biomarkers, it can help achieve more precise diagnoses, help analyze and integrate the increasing amount of data, support decision making and improve overall outcomes for patients in the long term.” said Anders Neijber, Chief Medical Officer of Photocure.
With NMIBC remaining a significant health concern globally, the integration of novel diagnostic technologies and AI promises to revolutionize diagnosis and treatment. By enhancing accuracy, integration of data, aiding risk stratification, and guiding personalized treatment approaches, these advancements offer hope for improved patient outcomes and more efficient disease management overall. While challenges such as data quality, cost, utility and regulatory hurdles exist, the trajectory is clear: the combination of AI and precision diagnostics procedures holds immense promise for transforming the landscape of NMIBC care in the years to come.
About Bladder Cancer
Bladder cancer ranks as the 8th most common cancer worldwide – the 5th most common in men – with 1 949 000 prevalent cases (5-year prevalence rate)1a, 614 000 new cases and more than 220 000 deaths in 2022.1b
Approx. 75% of all bladder cancer cases occur in men.1 It has a high recurrence rate with up to 61% in year one and up to 78% over five years.2 Bladder cancer has the highest lifetime treatment costs per patient of all cancers.3
Bladder cancer is a costly, potentially progressive disease for which patients have to undergo multiple cystoscopies due to the high risk of recurrence. There is an urgent need to improve both the diagnosis and the management of bladder cancer for the benefit of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion in the bladder wall. NMIBC remains in the inner layer of cells lining the bladder. These cancers are the most common (75%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has grown into deeper layers of the bladder wall. These cancers, including subtypes T2, T3 and T4, are more likely to spread and are harder to treat.4
1 Globocan. a) 5-year prevalence / b) incidence/mortality by population. Available at: https://gco.iarc.fr/today, accessed [February 2024].
2 Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
3 Sievert KD et al. World J Urol 2009;27:295–300
4 Bladder Cancer. American Cancer Society. https://www.cancer.org/cancer/bladder-cancer.html
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com